Pfizer Inc. (PFE) FCF Payout Ratio: 103.06%
Is Pfizer Inc.’s FCF payout ratio high or low?
Pfizer Inc.'s FCF payout ratio of 103.06% is 16% above its 5-year average of 88.95%, around the middle of its 5-year range (29.22%–192.93%).
The FCF payout ratio for Pfizer Inc. (PFE) is 103.06%. It is above its 12-month average by 0.85% (102.19%).
PFE FCF Payout Ratio Chart
PFE Average FCF Payout Ratio Chart
PFE Current vs Average FCF Payout Ratio Chart
PFE FCF Payout Ratio Metrics
FCF PAYOUT RATIO
103.06%
FCF PAYOUT RATIO AVG TTM
102.19%
FCF PAYOUT RATIO AVG 3Y
107.95%
FCF PAYOUT RATIO AVG 5Y
88.95%
FCF PAYOUT RATIO AVG 10Y
75.67%
FCF PAYOUT RATIO AVG 15Y
65.77%
FCF PAYOUT RATIO AVG 20Y
61.81%
CURRENT VS TTM AVG
+0.85%
CURRENT VS 3Y AVG
-4.53%
CURRENT VS 5Y AVG
+15.86%
CURRENT VS 10Y AVG
+36.19%
CURRENT VS 15Y AVG
+56.70%
CURRENT VS 20Y AVG
+66.73%
Payout Ratio Comparison
FCF Payout Ratio
103.1%
Earnings Payout Ratio
126.5%
Dividend Yield
6.70%
FCF Yield
6.45%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $9.08B | $9.77B | 107.7% |
| 2024 | $9.84B | $9.51B | 96.7% |
| 2023 | $4.79B | $9.25B | 192.9% |
| 2022 | $26.03B | $8.98B | 34.5% |
| 2021 | $29.87B | $8.73B | 29.2% |
| 2020 | $11.61B | $8.44B | 72.7% |
| 2019 | $9.99B | $8.04B | 80.5% |
| 2018 | $13.63B | $7.98B | 58.5% |
| 2017 | $14.25B | $7.66B | 53.7% |
| 2016 | $13.90B | $7.32B | 52.6% |
| 2015 | $13.02B | $6.94B | 53.3% |
| 2014 | $15.30B | $6.61B | 43.2% |
| 2013 | $16.30B | $6.58B | 40.4% |
| 2012 | $15.73B | $6.53B | 41.5% |
| 2011 | $18.58B | $6.23B | 33.6% |
| 2010 | $9.94B | $6.09B | 61.2% |
| 2009 | $15.38B | $5.55B | 36.1% |
| 2008 | $16.54B | $8.54B | 51.6% |
| 2007 | $11.47B | $7.97B | 69.5% |
| 2006 | $15.54B | $6.92B | 44.5% |
| 2005 | $12.63B | $5.55B | 44.0% |
| 2004 | $13.74B | $5.08B | 37.0% |
| 2003 | $9.10B | $4.35B | 47.8% |
| 2002 | $8.43B | $3.17B | 37.6% |
| 2001 | $7.06B | $2.71B | 38.5% |
| 2000 | $4.00B | $2.20B | 54.9% |
| 1999 | $1.50B | $1.15B | 76.8% |
| 1998 | $1.73B | $976.00M | 56.4% |
| 1997 | $686.00M | $881.00M | 128.4% |
| 1996 | $1.29B | $771.00M | 59.6% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Pfizer Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Pfizer Inc. (PFE)?
- The FCF payout ratio for PFE stock is 103.06%.
- Is Pfizer Inc.'s FCF payout ratio high or low?
- Pfizer Inc.'s FCF payout ratio of 103.06% is 16% above its 5-year average of 88.95%, around the middle of its 5-year range (29.22%–192.93%).
- What is the TTM average FCF payout ratio for Pfizer Inc. (PFE)?
- The TTM average FCF payout ratio for PFE stock is 102.19%.
- What is the 3Y average FCF payout ratio for Pfizer Inc. (PFE)?
- The 3Y average FCF payout ratio for PFE stock is 107.95%.
- What is the 5Y average FCF payout ratio for Pfizer Inc. (PFE)?
- The 5Y average FCF payout ratio for PFE stock is 88.95%.
- What is the 10Y average FCF payout ratio for Pfizer Inc. (PFE)?
- The 10Y average FCF payout ratio for PFE stock is 75.67%.
- What is the 15Y average FCF payout ratio for Pfizer Inc. (PFE)?
- The 15Y average FCF payout ratio for PFE stock is 65.77%.
- What is the 20Y average FCF payout ratio for Pfizer Inc. (PFE)?
- The 20Y average FCF payout ratio for PFE stock is 61.81%.
Pfizer Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 107.66% |
| 2024-12-31 | 96.72% |
| 2023-12-31 | 192.93% |
| 2022-12-31 | 34.51% |
| 2021-12-31 | 29.22% |
| 2020-12-31 | 72.68% |
| 2019-12-31 | 80.48% |
| 2018-12-31 | 58.53% |
| 2017-12-31 | 53.74% |
| 2016-12-31 | 52.63% |
| 2015-12-31 | 53.32% |
| 2014-12-31 | 43.20% |
| 2013-12-31 | 40.37% |
| 2012-12-31 | 41.55% |
| 2011-12-31 | 33.55% |
| 2010-12-31 | 61.24% |
| 2009-12-31 | 36.07% |
| 2008-12-31 | 51.65% |
| 2007-12-31 | 69.51% |
| 2006-12-31 | 44.51% |
| 2005-12-31 | 43.99% |
| 2004-12-31 | 36.99% |
| 2003-12-31 | 47.85% |
| 2002-12-31 | 37.60% |
| 2001-12-31 | 38.46% |
| 2000-12-31 | 54.87% |
| 1999-12-31 | 76.79% |
| 1998-12-31 | 56.38% |
| 1997-12-31 | 128.43% |
| 1996-12-31 | 59.63% |
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla